Components of NOTCH Signaling for Uterine Cancer Patients' Prognosis

Nadezda Lachej; Daiva Dabkeviciene; Julija Simiene; Rasa Sabaliauskaite; Violeta Jonusiene; Vytautas Brasiunas; Ausra Sasnauskiene; Ieva Vaicekauskaite; Birute Brasiuniene; Daiva Kanopiene; Kestutis Suziedelis; Janina Didziapetriene

doi:10.1155/2022/8199306

Components of NOTCH Signaling for Uterine Cancer Patients' Prognosis

J Oncol. 2022 Jan 30:2022:8199306. doi: 10.1155/2022/8199306. eCollection 2022.

Authors

Nadezda Lachej^{1

2}, Daiva Dabkeviciene^{2

3}, Julija Simiene^{2

3}, Rasa Sabaliauskaite², Violeta Jonusiene³, Vytautas Brasiunas², Ausra Sasnauskiene³, Ieva Vaicekauskaite^{2

3}, Birute Brasiuniene^{1

2}, Daiva Kanopiene², Kestutis Suziedelis^{2

3}, Janina Didziapetriene²

Affiliations

¹ Clinic of Internal Diseases, Family Medicine and Oncology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, LT-10257 Vilnius, Lithuania.
² National Cancer Institute, LT-08660 Vilnius, Lithuania.
³ Institute of Biosciences, Life Sciences Center, Vilnius University, LT-08412 Vilnius, Lithuania.

Abstract

New molecular biomarkers that could have an independent prognostic value in endometrial cancer are currently under investigation. Recently, it was suggested that genetic changes in the Notch signaling pathway could be associated with the development of endometrial carcinoma. This study aimed to determine the expression of the Notch signaling pathway components in tumour and adjacent normal uterine tissue and to evaluate their importance for the survival of uterine cancer patients. The present study was performed on uterine body samples collected from 109 patients and paired adjacent noncancerous endometrial tissue samples. Kaplan-Meier curves and Cox regression were used for survival analyses. Expression alterations of NOTCH2, NOTCH3, NOTCH4, JAG2, and HES1 were evaluated as independent and significant prognostic factors for uterine cancer patients.